Sorafenib (Nexavar, sorafenib tosylate, BAY 43-9006)
Brand Name: Nexavar
Generic Name: sorafenib tosylate
Code Name: BAY 43-9006
Company: Bayer
FDA Clinical Phase: 1, 2
Description:
Sorafenib is a kinase inhibitor that stops cells from dividing and may also prevent the growth of new blood vessels that tumors need for growth (known as angiogenesis). Sorafenib is a drug used to treat advanced kidney cancer and a type of liver cancer. It is also being studied for treating other cancers.
Clinical Trials:
Currently, there are two clinical trials with sorafenib recruiting patients. One study is using a combination of Sorafenib and Everolimus. Another study is a Phase 1 trial using Sorafenib in combination with Velcade (bortezomib). Both clinical trials are recruiting adults and senior patients of both genders.
Source: http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=390251
Related Articles:
- Getting To Know: Tiragolumab
- bb2121 Continues To Impress As Potential New Multiple Myeloma Therapy (ASCO 2018)
- Darzalex May Affect Different Uninvolved Immunoglobulins Differently
- Common Measures Of Heart And Blood Vessel Health May Predict Risk Of Heart-Related Side Effects During Treatment With Kyprolis
- Two Darzalex Clinical Trials Halted; Little Impact Expected On Drug’s Use In Multiple Myeloma